Cellectar: Complete CNS Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies

In its Phase 2b CLOVER WaM pivotal trial.

https://www.globenewswire.com/news-release/2024/01/22/2812874/0/en/Cellectar-Biosciences-Reports-Complete-Central-Nervous-System-CNS-Clearance-in-Relapsed-Refractory-Waldenstrom-s-Macroglobulinemia-Patient.html